Todd Brady, M.D.

Principal, Domain Associates
Dr. Brady joined Domain in 2004. Present board memberships include Asmacure, Evoke Pharma, Neuron Systems, Novadigm Therapeutics, ParinGenix. In addition, he is on the grant review board for the New Jersey Commission on Science and Technology, the venture capital advisor to the New Jersey Biotechnology Council Board of Trustees, a member of the Southeast BIO Board of Directors, and an advisor to the Translational Science Institute at Wake Forest University. Prior to Domain, Dr. Brady was co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later Executive Vice President of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now part of UCB). Dr. Brady holds an A.B from Dartmouth College, a Ph.D. from Duke University and an M.D. from Duke University Medical School.